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2ABSTRACT23
Despite advances in our understanding of the molecular basis for particular subtypes of acute24
myeloid leukemia (AML), effective therapy remains a challenge for many individuals25
suffering from this disease. A significant proportion of both pediatric and adult AML patients26
cannot be cured and since the upper limits of chemotherapy intensification have been27
reached, there is an urgent need for novel therapeutic approaches. The transcription factor c-28
MYB has been shown to play a central role in the development and progression of AML29
driven by several different oncogenes, including mixed lineage leukemia (MLL)-fusion genes.30
Here, we have used a c-MYB gene expression signature from MLL-rearranged AML to probe31
the Connectivity Map database and identified mebendazole as a c-MYB targeting drug.32
Mebendazole induces c-MYB degradation via the proteasome by interfering with the heat33
shock protein 70 (HSP70) chaperone system. Transient exposure to mebendazole is sufficient34
to inhibit colony formation by AML cells, but not normal cord blood-derived cells.35
Furthermore, mebendazole is effective at impairing AML progression in vivo in mouse36
xenotransplantation experiments. In context of the widespread human use of mebendazole,37
our data indicate that mebendazole induced c-MYB degradation represents a safe and novel38
therapeutic approach for AML.39
3INTRODUCTION40
Rational combination of intensive chemotherapy with risk stratification has revolutionized41
the treatment of acute leukemia in children. However, progress has not been uniform across42
all subtypes of disease and many pediatric1 and adult2 Acute Myeloid Leukemia (AML)43
patients cannot be cured by current therapies. It is widely accepted that further intensification44
of chemotherapy is unlikely to improve outcomes,3, 4 but that this may be achieved by45
developing novel therapeutics targeting specific leukemia drug-susceptibilities.46
Rearrangements of the MLL gene are often associated with AML in children, and less47
frequently in adults.5 These abnormalities result in generation of MLL fusion proteins, which48
are responsible for driving development of the disease. These proteins hijack the normal49
epigenetic machinery in developing hematopoietic cells, enforcing transcriptional50
dysregulation of target genes.6-9 Identification of components of the MLL fusion-associated51
complexes led to a number of drug discovery initiatives.10, 11 Recent studies indicate that one52
transcriptional target in particular, encoding the transcription factor c-MYB, is responsible53
for maintaining aberrant hematopoietic self-renewal programs necessary for initiation and54
progression of MLL-rearranged AML.12-1555
c-MYB is highly expressed in immature hematopoietic progenitor cells and is required for56
definitive hematopoiesis,16 normal myelopoiesis17 and maintenance of adult hematopoietic57
stem cell (HSC) self-renewal.18 c-MYB is rarely mutated in human leukemia, but has long58
been associated with hematopoietic malignancies.19, 20 Some leukemia cells have been shown59
to be more sensitive to c-MYB inhibition than normal hematopoietic cells.21, 22 This led to the60
hypothesis that although it may not be an oncogenic driver itself, certain cancers are61
nevertheless ‘addicted’ transcriptional dysregulation by c-MYB.23 In contrast to absolute c-62
MYB deficiency, low levels of c-MYB expression are compatible with limited63
4hematopoiesis, especially myelopoiesis,15, 24 suggesting that a window may exist for64
therapeutic targeting of c-MYB in AML. However, difficulties associated with developing65
small molecule inhibitors of transcription factor activity suggest that alternative approaches66
may be required to target c-MYB.19 For example, the interaction between c-MYB and the67
transcriptional co-activator p300 was recently shown to be essential for AML induction25 and68
to have promising potential as a target for pharmacological inhibition.2669
In order to identify bioactive compounds capable of inhibiting c-MYB transcriptional70
activity in AML, we screened the Connectivity Map (CMAP) database with a c-MYB gene71
expression signature derived from integrating MLL-fusion protein specific gene expression72
changes with a list of previously published direct c-MYB target genes.27, 28 This analysis73
identified the anti-helminth drug mebendazole as the top hit. We demonstrate that74
mebendazole induces proteasomal degradation of c-MYB, inhibits AML cell self-renewal75
and impairs AML progression in vivo. This work demonstrates that mebendazole has76
excellent potential for repurposing in novel AML therapies.77
78
5MATERIALS AND METHODS79
Mice80
Mice were maintained in the UCL GOSICH animal facilities and experiments were81
performed according to and approved by the United Kingdom Home Office regulations and82
followed UCL GOSICH institutional guidelines.83
84
Human samples85
For human AML samples (Supplementary Table 1), approval by the Institutional Review86
Board of the Erasmus MC for use of excess diagnostic material was obtained according to87
laws and regulations of the Netherlands, DB AML 01 (MEC-2010-370), AML NOPHO DBH88
2012 (MEC-2014-024).89
90
Global gene expression, SPIEDw and Gene set enrichment (GSEA) analyses91
Analysis of MLL-ENL/MLL-AF9 gene expression changes (Geo repository: GSE59236) was92
performed using Affymetrix arrays (Affymetrix UK, High Wycombe, UK) and conditionally93
immortalized MLL-ENL and MLL-AF9 mouse myeloid cells.29-32 Gene expression changes94
resulting from 6 hours exposure of THP1 cells to 10 M mebendazole or DMSO were95
analysed by RNA-sequencing (Geo repository: GSE96544). A list (Supplementary Table 2)96
of human orthologs of MLL-ENL/MLL-AF9 gene expression changes, for genes also97
contained in the list of 1063 genes bound by c-MYB in mouse myeloid ERMYB cells27 and98
deregulated in THP1 cells following siRNA-mediated c-MYB silencing,28 were used to99
interrogate the CMAP database (https://portals.broadinstitute.org/cmap/)33 using the SPIEDw100
web tool34 (http://www.spied.org.uk/). For GSEA, c-MYB signatures were derived from101
Zhao et al.27 and LSC signatures from Somervaille et al.13102
103
6104
Cell culture and reagents105
Human AML cell lines were purchased from the ATCC (THP1) and DSMZ (OCI-AML3,106
NOMO-1, KCL22, U937, MV4;11, KASUMI-1 and SHI-1), authenticated by short tandem107
repeat profiling using the PowerPlex 16 system (Promega, Southampton, UK) and108
mycoplasma negative status confirmed using the MycoAlert Mycoplasma Detection Kit109
(Lonza, Verviers, Belgium). 293FT cells were from ThermoFisher Scientific (ThermoFisher110
Scientific, Hemel Hempstead, UK) and immortalized mouse myeloid cells were cultured as111
previously described.29-32112
113
Colony formation assays114
AML cell lines were plated in HSC002 (Bio Techne, Abingdon, UK), normal CD34+ cord115
blood-derived cells (ZenBio, NC, USA) in HSC005 (Bio Techne) and primary AML cells in116
HSC005 methylcellulose medium supplemented with 50 ng/ml TPO and FLT3L.117
118
Nematic protein organisation technique (NPOT) analysis119
NPOT analysis was performed by INOVIEM Scientific (INOVIEM Scientific, Strasbourg,120
France).121
122
In vivo transplantation123
Luciferase expressing THP1 cells were transplanted into non-irradiated NOD-SCID--/-124
(NSG; The Jackson Laboratory, Bar Harbor, ME, USA) mice. Recipient mice were imaged125
using the IVIS® Lumina Series III (PerkinElmer, Beaconsfield, UK) and randomly allocated126
to control or mebendazole-treated groups. Mebendazole (200 mg/kg of diet) was127
administered ad libitum in regular powdered diet, changed daily.128
7129
Lentivirus vector cloning130
The MYB cDNA35 was cloned into the pCSGW-PIG vector, made by replacing the GFP131
cDNA from pCSGW36 with a puro-IRES-GFP cassette. Lentiviral MISSION shRNA132
constructs targeting c-MYB (Clone ID:NM_005375.2-927s21c1), HSPA1A (sh1:Clone133
ID:NM_005345.4-1539s1c1; sh2:Clone ID:NM_005345.4-566s1c1) and the scramble (SCR)134
non-silencing control (SHC002) were purchased from Sigma-Aldrich (Gillingham, UK).135
136
Western blot analysis137
Antibodies against c-MYB (H-141, catalogue number sc-7874, Santa Cruz Biotechnology,138
Dallas, TX, USA; clone 1-1, catalogue number 05-175, Merck Millipore, Watford, UK;139
EPR718(2), catalogue number ab109127 , Abcam, Cambridge, UK), HSP70 (clone 242707,140
catalogue number MAB1663, Bio Techne), HSP70/HSC70 (and H-300, catalogue number sc-141
33575, and W27, catalogue number sc-24, Santa Cruz Biotechnology), Actin (I-19, catalogue142
number sc-1616, Santa Cruz Biotechnology), -Actin (C4, catalogue number sc-47778, Santa143
Cruz Biotechnology), Tubulin (YL1/2, catalogue number sc-53029, Santa Cruz144
Biotechnology), SP1 (PEP 2, catalogue number sc-59, Santa Cruz Biotechnology) .145
146
Microtubule depolymerization assay147
Microtubule depolymerization was analysed as published previously.37148
149
Quantitative RT-PCR analysis150
Quantitative RT-PCR (qPCR) was performed on isolated mRNA using TaqMan probe based151
chemistry and an ABI Prism 7900HT fast Sequence Detection System (Life Technologies,152
Paisley, UK). All primer/probe sets were from Applied Biosystems, Life Technologies.153
8154
Statistics155
Statistical significance was determined using Prism (GraphPad) software. Statistical analysis156
of survival curves was performed using the Mantel-Haenszel log-rank test. Statistical analysis157
of means was performed using the one sample t test or unpaired Student’s t test, two-tailed P158
values < 0.05 being considered statistically significant. Variance was similar between groups.159
160
Further details are provided in Supplementary Materials and Methods.161
162
9RESULTS163
To identify candidate anti-leukemia drugs, we generated a therapeutic signature164
(Supplementary Table 2) by integrating gene expression changes due to MLL fusion165
silencing29-32 with transcriptional regulation by c-MYB in acute myeloid leukemia.27, 28 This166
signature was then used to interrogate drug-induced gene expression profiles in the CMAP167
database33 using the SPIEDw web tool34 (Figure 1a). The top hit resulting from this analysis168
was the anti-helminth agent mebendazole (Figure 1b).169
In order to determine whether mebendazole was able to interfere with c-MYB regulated170
transcriptional pathways in human AML cells, RNASeq was performed on the MLL-AF9171
expressing cell line THP1, following short-term exposure to the drug. GSEA of mebendazole172
induced gene expression changes confirmed that this drug was able to reverse both activation173
and repression by c-MYB of its target genes (Figure 1c and Supplementary Figure 1).174
Mebendazole exhibited anti-leukemia activity against MLL rearranged and non-rearranged175
human AML cell lines (Figure 2a and Supplementary Figure 2) and was effective at blocking176
their colony forming activity (Figure 2b and Supplementary Figure 3). This is not surprising,177
since c-MYB has also been shown to play a critical function in non-rearranged subtypes of178
AML.25, 26, 38-41 Indeed, shRNA mediated silencing of c-MYB expression had a severe impact179
on colony formation (Supplementary Figure 4).180
We then examined whether mebendazole interfered with c-MYB regulated gene181
expression by targeting the transcription factor directly, by examining RNA and protein182
expression 6 hours after exposure of AML cells to the drug. Interestingly, mebendazole183
inhibited c-MYB protein expression in all cell lines examined, and RNA expression in some184
(Figure 3a). c-MYB protein expression was affected at lower concentrations of mebendazole185
than those required to inhibit RNA expression, and occurred without any change in RNA186
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expression in some cells, suggesting that mebendazole targets c-MYB expression primarily at187
the protein level. Indeed, reversal of c-MYB protein loss by proteasomal inhibition indicates188
that mebendazole targets c-MYB for proteasomal degradation (Figure 3b and Supplementary189
Figure 5).190
There has been considerable interest recently in repurposing mebendazole for cancer191
therapy.42 However, the mechanism for its anti-cancer activity has remained elusive. Initially192
this was thought to derive from its microtubule destabilizing activity, mebendazole binding193
tubulin at the colchicine-site,43 although recent experiments have suggested alternative194
mechanisms.44 We compared microtubule depolymerization and c-MYB degradation induced195
by mebendazole in AML cells to that resulting from treatment of the cells with the196
microtubule disrupting agent colcemid (Figure 4a and Supplementary Figure 6). Equivalent197
concentrations of colcemid induced both microtubule depolymerization and loss of c-MYB198
protein. In contrast, mebendazole induced c-MYB degradation at concentrations that do not199
cause microtubule depolymerization, indicating that the former is not a result of the latter per200
se.201
Exactly how mebendazole induces c-MYB degradation is unclear. It does not appear to be202
a secondary consequence of a cell cycle block, since c-MYB loss is already evident in THP1203
cells after 4 hours mebendazole exposure, prior to drug-induced changes in cell cycle profiles204
(Supplementary Figure 7). In order to address this question, nematic protein organisation205
technique (NPOT) analysis (Inoviem Scientific) of mebendazole was performed using cell206
lysates from a primary AML patient sample and THP1 cells (Supplementary Figures 8a and207
8b). DAVID analysis of the proteins identified in the AML patient sample hetero-assemblies,208
induced by mebendazole, highlighted ‘protein folding’ as the second most significant209
functional category, with 12 of the 16 proteins in this category also identified in THP1210
hetero-assemblies (Supplementary Figure 8c). This suggests that mebendazole disrupts the211
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cellular protein folding machinery leading to the proteasomal targeting of c-MYB (Figure212
3b). Of particular interest were a number of proteins of the HSP70/HSP90 chaperone213
complexes. c-MYB has previously been shown to be an HSC70 client protein in prostate214
cancer cells.45, 46 Indeed, we found that the HSP70/HSC70 chaperone complex is also215
associated with c-MYB in AML cells (Figure 4b and Supplementary Figure 9a), an216
association that was lost upon exposure to mebendazole (Figure 4c). Furthermore, HSPA1A217
knockdown and pharmacological HSP70 inhibition resulted in reduced c-MYB protein levels218
(Figure 4d and Supplementary Figure 9b and 9c). However, mebendazole did not induce any219
changes in expression levels or subcellular re-localization of the HSP70/HSC70 complex220
(Supplementary Figure 9d).221
Since c-MYB has been placed at the center of a leukemia stem cell (LSC) transcriptional222
self-renewal program in MLL-rearranged leukemia,13 we hypothesized that mebendazole223
treatment of MLL-rearranged AML cells would inhibit this program. Indeed, GSEA analysis224
of gene expression changes following treatment of THP1 cells with mebendazole225
demonstrated negative enrichment of the LSC self-renewal signature (Figure 5a). In order to226
examine whether short-term exposure to mebendazole would indeed compromise AML cell227
self-renewal, we treated THP1 cells with 10M mebendazole for 16 hours, washed them and228
examined their colony forming potential in vitro. Consistent with the observed inhibition of229
the LSC self-renewal program, transient exposure to mebendazole resulted in a more than230
80% reduction in colony formation by THP1 cells (Figure 5b). Our hypothesis predicts that231
stabilization of the c-MYB protein would have the potential to rescue this loss of self-renewal232
induced by mebendazole. In order to examine this possibility, we generated a C-terminal233
deletion mutant of c-MYB (MYB), previously shown to result in enhanced protein234
stability,35 and expressed this mutant in THP1 cells. MYB was partially protected from235
mebendazole-induced degradation (Figure 5c). Since the mutant contained the unaltered236
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DNA-binding domain, which is necessary for the transcriptional activity of c-MYB, but237
which contains residues known to be targeted by ubiquitin-mediated proteasomal238
degradation,47 it is not surprising that it was not completely resistant to mebendazole.239
However, MYB expressing THP1 cells were found to express higher levels of total c-MYB240
protein than control THP1 cells, following 6 hours treatment with mebendazole (Figure 5c).241
Importantly, this partial rescue of c-MYB protein expression correlated with increased colony242
forming potential of MYB expressing THP1 cells following transient exposure to243
mebendazole (Figure 5d). These data indicate that mebendazole inhibits AML colony244
formation by disrupting the c-MYB regulated LSC self-renewal program. Interestingly,245
transient mebendazole exposure also inhibited in vitro colony formation by two independent246
MLL-AF9 expressing primary AML patient samples, but had no significant effect on colony247
formation by normal CD34+ cord blood cells (Figure 5e and Supplementary Figure 10).248
Interestingly, mebendazole only caused partial loss of c-MYB in the latter (Supplementary249
Figure 11).250
Having shown the anti-leukemia activity of mebendazole in vitro, we decided to test251
whether it could make an impact on AML disease progression in vivo. Oral administration of252
mebendazole, by simply mixing the drug in the diet, was found to have significant activity253
against disease in THP1 transplanted NSG mice, inhibiting leukemia progression (Figures 6a254
and b) and prolonging survival of treated mice (Figure 6c). Interestingly, THP-1 cells isolated255
from mebendazole-treated mice were found to express increased c-MYB protein levels and to256
be more resistant to drug treatment (Supplementary Figure 12). These data indicate that oral257
administration of mebendazole is sufficient to significantly impair AML progression in vivo.258
259
260
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DISCUSSION261
Our data show that mebendazole induces degradation of the transcription factor c-MYB. c-262
MYB is essential for survival and self-renewal of multiple AML subtypes. c-MYB263
degradation results in loss of AML cell viability, colony formation and impaired in vivo264
leukemia progression. The rescue of AML cells from the inhibition of colony formation,265
following transient exposure to mebendazole, by over-expression of the MYB mutant266
highlights the significance of c-MYB degradation in the anti-AML effects of this drug.267
Although, the MYB mutant exhibits enhanced protein stability,35 it is not completely268
resistant to mebendazole induced degradation, potentially explaining why the rescue of269
colony formation is only partial. It is likely that mebendazole interferes with multiple270
pathways in cancer cells44 and it has been suggested to be a promising candidate for anti-271
cancer drug repurposing.42 However, the induction of c-MYB degradation by mebendazole272
makes it particularly suitable to repurposing into AML therapy.273
Some solid cancers are also addicted to continued and relatively high expression of the274
oncoprotein c-MYB. This is particularly evident in colorectal cancer where c-MYB is over-275
expressed and essential to continued proliferation and tumor cell survival.19 In a recent study,276
mebendazole showed activity in the majority of the colon cancer cell lines tested.44 It is277
noteworthy that a patient with refractory metastatic colon cancer treated with mebendazole278
showed near complete remission of the metastases in the lungs and lymph nodes and a good279
partial remission in the liver.48 This suggests that mebendazole induced proteolysis of c-MYB280
may also have major clinical implications outside of AML therapy, in the treatment of a281
variety of cancers.282
Induction of c-MYB degradation by mebendazole is blocked by proteasomal inhibition283
and occurs at much lower concentrations than those necessary to achieve microtubule284
14
depolymerization in AML cells. We present evidence for the involvement of the285
HSP70/HSC70 chaperone complex in c-MYB targeting by mebendazole. The complex was286
found to bind c-MYB in AML cells, an association that was lost upon exposure of cells to287
mebendazole. Pharmacological or shRNA directed inhibition of HSP70 also resulted in loss288
of c-MYB protein. Interestingly, the HSP70/HSC70 complex has previously been shown to289
interact with c-MYB in prostate cancer cells, its displacement form the complex by glioma290
pathogenesis-related protein 1 (GLIPR1) over-expression resulting in c-MYB protein291
destabilization.45, 46292
In summary, we have used Connectivity Map analysis to identify mebendazole as a novel293
candidate anti-AML therapeutic. Our data highlight a hitherto unappreciated link between294
microtubule interacting agents and the regulation of c-MYB protein degradation. Importantly,295
widespread use of mebendazole is tolerated in children and adults across the world,49296
suggesting that this drug has real potential for safe use in the treatment of human AML.297
298
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FIGURE LEGENDS449
Figure 1. Identification of mebendazole as a c-MYB targeting drug in AML. (a) Diagram450
summarizing the generation of a c-MYB signature used to interrogate the CMAP database 33451
using SPIEDw34. (b) The 1,309 CMAP drugs are ranked based on the significance of452
regression scores between their transcriptional profiles and that of the query. The Z-score453
corresponds to the number of standard deviations of the score away from the mean. Inset is454
the structure of mebendazole (rank 1). (c) GSEA of the c-MYB activated (top) and repressed455
(bottom) gene sets in global gene expression changes in THP1 cells following 6 hours456
exposure to 10 M mebendazole (MBZ) versus DMSO.457
Figure 2. Mebendazole inhibits AML growth and colony formation. (a) Viability, normalized458
to DMSO controls, of AML cell lines treated for 72 hours with indicated mebendazole459
concentrations. Bars and error bars are means and SD of three independent experiments, each460
in triplicate. (b) Examples of AML cell line colony formation in methylcellulose cultures in461
the presence of DMSO or 1.25 M mebendazole (quantification in Supplementary Figure 1).462
Figure 3. Mebendazole induces proteasomal degradation of c-MYB. (a) Protein and RNA463
expression in AML cells after 6 hours treatment with DMSO or indicated mebendazole464
concentrations, normalized to DMSO controls. Bars and error bars are means and SD of three465
independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant (relative466
to DMSO controls), one sample t test. Western blots below graphs show examples of c-MYB467
protein expression. (b) Western blot analysis of c-MYB protein expression in AML cells after468
6 hours treatment with DMSO, 10 M mebendazole or 10 M mebendazole and 10 M469
MG132 (quantification in Supplementary Figure 3).470
Figure 4. Mebendazole destabilizes c-MYB protein by interfering with the HSP70/HSC70471
chaperone pathway. (a) Percent polymerized tubulin in THP1 cells following 6 hours472
24
treatment with indicated concentrations of mebendazole (top left) or colcemid (top right), and473
western blot analysis of corresponding c-MYB protein expression (bottom). Tubulin474
stabilization by 5 M paclitaxel (Pax) is also shown. Bars and error bars are means and SD of475
three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant,476
unpaired Student’s t-test. (b) Western blot analysis of mouse IgG and anti-HSP70/HSC70477
immunoprecipitates from THP1 cells, stained with anti-c-MYB (top) and anti-HSP70/HSC70478
(bottom). Representative data from one of three independent experiments. (c) Western blot479
analysis of anti-HSP70/HSC70 immunoprecipitates from THP1 cells following 6 hours480
treatment with DMSO or 10 M mebendazole, stained with anti-c-MYB (top) and anti-481
HSP70/HSC70 (bottom). Representative data from one of three independent experiments. (d)482
Western blot analysis of HSP70 (top) and c-MYB (middle) expression in THP1 cells 7 days483
after transduction with control scramble (shSCR) shRNA or two independent shRNA484
targeting HSPA1A (sh1 and sh2) (quantification in Supplementary Figure 7b).485
Figure 5. Transient exposure to mebendazole inhibits colony formation by AML but not486
normal cord blood-derived hematopoietic cells. (a) GSEA of the gene expression signatures487
positively (top) and negatively (bottom) correlating with leukemia stem cell frequency 13 in488
global gene expression changes in THP1 cells following 6 hours exposure to 10 M489
mebendazole versus DMSO. (b) Example of THP1 colony formation after pre-treatment with490
DMSO or 10 M mebendazole. Cells were treated with vehicle or drug for 16 hours, washed491
and placed into methylcellulose culture. The mean (± SD) fold change in colony formation is492
shown from five independent experiments, normalized to DMSO controls. ***P < 0.001493
(relative to DMSO controls), one sample t test. (c) c-MYB protein expression in empty vector494
(Con) or c-MYB deletion mutant (MYB) transduced THP1 cells, 6 hours after treatment495
with DMSO or 10 M mebendazole. (d) Fold change in colony formation by Con or MYB496
transduced THP1 cells, following 16 hours pre-treatment with DMSO or 10 M497
25
mebendazole, normalized to Con or MYB DMSO controls. Bars and error bars are means498
and SD of seven independent experiments. ***P < 0.001, unpaired Student’s t-test. (e)499
Colony formation frequency by two independent primary AML patient samples (AML1547,500
AML1497) and two independent normal CD34+ cord blood samples (CB1, CB2) after pre-501
treatment with DMSO or 10 M mebendazole. Cells were treated with vehicle or drug for 20502
hours, washed and placed into methylcellulose culture.503
Figure 6. Mebendazole impairs AML progression in vivo. (a) Bioluminescence imaging of504
NSG recipient mice 10 days after injection with THP1-LUC2 cells, and before drug505
treatment, (day 0, top), and 22 days after treatment with normal or mebendazole-containing506
diet (bottom). Bars for luminescence signal represent photons/s/cm2/steradian. (b)507
Luminescence signal in treatment groups, 10 days after THP1-LUC2 cell injection and before508
drug treatment (left), and fold increase in luminescence signal in the groups 7 and 17 days509
after treatment with normal or mebendazole-containing diet (right). Bars and error bars are510
means and SD of values form control (n = 5) and mebendazole-treated (n = 9) groups. ***P <511
0.001; n.s. not significant, unpaired Student’s t-test. (c) Survival curve for control (n = 9) and512
mebendazole-treated (n = 12) mice, P < 0.0001, Mantel-Haenszel log-rank test.513
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1SUPPLEMENTARY MATERIALS AND METHODS
Mice
All mice were maintained in the animal facilities of the UCL Great Ormond Street Institute of
Child Health, London. All mouse experiments were performed according to and approved by
the United Kingdom Home Office regulations and followed UCL Great Ormond Street
Institute of Child Health institutional guidelines.
Human samples
Primary AML mononuclear cells were isolated by sucrose gradient centrifugation
(Lymphoprep, 1.077 g/ml density; Nycomed Pharma).
Global gene expression analysis
Conditionally immortalized MLL-ENL and MLL-AF9 mouse myeloid cells have been
previously described.1-4 Control constitutive and conditionally immortalized cells were
treated with 2 g/ml doxycycline for 48 hours, RNA extracted using TRIzol reagent
(ThermoFisher Scientific) and quality verified using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Wokingham, UK). RNA was hybridized to GeneChip Mouse Genome 430.2
arrays (Affymetrix). Data was analyzed using GeneSpring 7.3.1 software (Agilent
Technologies). Gene expression changes of more than 2-fold, with a defined P-value cut-off
≤ 0.05, upon treatment with doxycycline were selected. Genes whose expression changed 
more than 2-fold in constitutive cells, upon doxycycline treatment, were excluded. Duplicate
probe sets were removed, keeping those with the highest fold change. THP1 cells were
cultured at 0.5 x 106 cells/ml and treated with 10 M mebendazole or DMSO control, for 6
hours. RNA was purified and submitted to UCL Genomics for RNA-sequencing. Samples
were processed using an Illumina TruSeq RNA sample prep kit Version 2 (RS-122-2001)
2according to manufacturer’s instructions (Illumina, Cambridge, UK) and sequenced on an
Illumina NextSeq 500 (Illumina). Differential expression was obtained using the RNA
Express BaseSpace® app (Illumina). Low expressed genes were removed from the output
file. This was used for GSEA analysis.
Gene expression changes for SPIEDw analysis
MLL-ENL/MLL-AF9 gene expression changes, for genes also contained in the list of 1063
genes bound by c-MYB in mouse myeloid ERMYB cells5 and deregulated in THP1 cells
following siRNA-mediated c-MYB silencing,6 were selected. These genes were converted
into human gene names using the HGNC Comparison of Orthology Predictions (HCOP)
search tool,7 using the HGNC orthologs. This list (Supplementary Table 2) was then used to
interrogate the CMAP database (https://portals.broadinstitute.org/cmap/)8 using the SPIEDw
web tool9 (http://www.spied.org.uk/), which allows queries to be entered as gene names
rather than probe sets.
Gene set enrichment analysis
c-MYB signatures5 were genes bound by c-MYB in mouse myeloid ERMYB cells and
deregulated in THP1 cells following siRNA-mediated c-MYB silencing,6 either decreasing in
expression (MYB activated) or increasing in expression more than 1.5-fold (MYB repressed).
LSC signatures10 consisted of probe sets positively correlated with LSC frequency (LSC
POS) and negatively correlated with LSC frequency (LSC NEG). Mouse gene names were
converted into human gene names using the HCOP using the HGNC orthologs, as above.
Cell culture and reagents
3Human AML cell lines were cultured in RPMI or IMDM (SHI-1) supplemented with 10–
20% FCS, L-glutamine and penicillin/streptomycin. 293FT (ThermoFisher Scientific) cells
were maintained in DMEM with 10% FCS, L-glutamine, penicillin/streptomycin and 500
g/ml G418. For some experiments, CD34+ cord blood-derived cells (ZenBio) were
expanded in StemSpan SFEM II medium (StemCell Technologies, Grenoble, France)
supplemented with 100 ng/ml human SCF, TPO and FLT3L (all from Peprotech, London,
UK).
Colony formation assays
AML cell lines were plated out in HSC002 methylcellulose medium (Bio Techne) at 150-500
cells/well in 24-well plates. Colonies were grown for 7-14 days and visualized by staining
with 1 mg/ml p-iodonitrotetrazolium. For pre-stimulation, primary AML cells and normal
CD34+ cord blood-derived cells (ZenBio) were cultured with DMSO or 10 M mebendazole
for 20 hours in IMDM with 10% FCS, L-glutamine, penicillin/streptomycin. AML cells were
supplemented with 100 ng/ml human SCF, TPO and FLT3L, 10 ng/ml IL3, IL6 and IL11,
and CD34+ cord blood-derived cells with 100 ng/ml human SCF, TPO and FLT3L (all
growth factors were form Peprotech). Cells were plated out into HSC005 methylcellulose
medium (Bio Techne) containing 50 ng/ml human SCF, 20 ng/ml IL3, IL6, G-CSFD, GM-
CSF and 3 IU/ml EPO at 300-1000 cells/well in 35 mm plates. Primary AML methylcellulose
cultures were further supplemented with 50 ng/ml TPO and FLT3L. Cultures were counted
and morphology scored 14 days later.
Growth, apoptosis and cell cycle assays
The effect of mebendazole on growth of AML cell lines was examined by exposing them to
different concentrations of mebendazole in liquid culture, starting at 1.25-2.5 x 105 cells/ml,
4and 72 hours later were stained with TO-PRO®-3 (ThermoFisher Scientific) stain and total
viable cells were determined by flow cytometry analysis on a BD FACSArray™ Bioanalyzer,
using Summit 4.3 software (Beckman Coulter, High Wycombe, UK). Apoptosis was detected
using the Annexin V Apoptosis detection kit (eBioscience, Hatfield, UK). Cell cycle analysis
was performed using the Click-iT EdU Alexa Flour 647 Flow Cytometry Assay Kit
(Invitrogen, Life Technologies). Cells were analyzed on an LSRII (BD Bioscience, San Jose,
CA, USA), and the data were analyzed with Summit 4.3 software (Beckman Coulter).
Nematic protein organisation technique (NPOT) analysis
NPOT is a label free proprietary technology offered by INOVIEM Scientific, used to isolate
and identify specific macromolecular scaffolds implemented in basic or pathological
situations directly from human tissue. Specifically, primary AML sample AML4298 and
THP1 cell homogenates were prepared under low temperature (4°C) in the absence of any
detergent, reducing agent or protease or phosphatase inhibitors. All dilutions and washes
were performed in HBSS with osmolality, trace elements, vitamins and salts concentrations
as close as possible to those of the interstitial medium or cellular cytoplasm. Mebendazole
(1µM) was added to the total tissue material. The macromolecular assemblies related to the
specific ligands were then separated using a differential microdialysis system, based on liquid
transitory pH gradient (pH5-10) where the macromolecules (protein groups) can migrate in
the liquid phase to their mean molecular zwitterion positions.11-14 The gradually growing and
migrating macromolecules will form nematic crystals to macromolecular hetero-assemblies
thanks to the molecular interactions between the ligand(s) and their targets. The hetero-
assemblies are then trapped in mineral oil and isolated and identified by mass spectroscopy
directly in liquid. Formation of hetero-assemblies and crystals were induced by addition of
mebendazole and did not form in its absence.
5In vivo transplantation
THP1 cells were transduced with a lentivirus vector containing a luciferase (LUC2)-IRES-
EGFP cassette, and EGFP+ cells purified by flow cytometric sorting. 1-2 x 106 THP1-LUC2
cells were transplanted into non-irradiated 6-12 week old male NOD-SCID--/- (NSG; The
Jackson Laboratory) mice by lateral tail vein injection. Recipient mice were imaged 10
minutes following subcutaneous injection of 5 mg/mouse D-luciferin (Cayman Chemical
Company, Ann Arbor, MI, USA) using the IVIS® Lumina Series III pre-clinical in vivo
imaging system (PerkinElmer) and randomly allocated to control or mebendazole-treated
groups by flipping a coin. Mebendazole (200 mg/kg of diet) was administered ad libitum in
regular powdered diet, changed daily. Group sizes were chosen based on previous estimates
of disease latency in THP1 transplanted mice and experiments in the literature performing
similar studies. No mice were excluded from the analysis. No blinding was used in group
allocation or analysis of data.
Lentivirus vector cloning, production and transduction of cell lines
The MYB cDNA15 was cloned into the pCSGW-PIG vector, made by replacing the GFP
cDNA from pCSGW16 with a puro-IRES-GFP cassette, and the resulting vector used to
transduce THP1 cells. The luciferase (LUC2) cDNA was cloned into pCSGW. Lentiviral
MISSION shRNA constructs targeting c-MYB (Clone ID:NM_005375.2-927s21c1),
HSPA1A (sh1:Clone ID:NM_005345.4-1539s1c1; sh2:Clone ID:NM_005345.4-566s1c1)
and the scramble (SCR) non-silencing control (SHC002) were purchased from Sigma-
Aldrich. The 293FT packaging cells (ThermoFisher Scientific) were transiently cotransfected
with the lentiviral expression vectors, the pCMV-PAX2 construct and the pVSV-G envelope
construct (kind gifts of D. Trono, Lausanne, Switzerland). Human leukemia cells were
6transduced with lentiviral supernatant by spinoculation at 700g, 25°C for 45 minutes in the
presence of 5 g/mL polybrene. Transduced cells were selected in puromycin for 72 hours.
Western blot analysis
Cells were lysed in reducing sample buffer (100 mM dithiothreitol, 2% sodium dodecyl
sulfate, 10 % glycerol, 0.002 % bromophenol blue, 62.5 mM Tris-HCL pH 6.8). Nuclear and
cytoplasmic lysates were prepared using the Nuclear Extract kit (Active Motif, La Hulpe,
Belgium). Protein samples were resolved on gels 10 % polyacrylamide (0.36 M bis-Tris, 10
% acrylamide/bis) in MOPS-SDS running buffer (50 mM Tris, 50 mM MOPS, 1 mM EDTA,
0.1 % SDS). Gels were transferred onto a PVDF (Merck Millipore) or nitrocellulose (LI-
COR Biosciences, Cambridge, UK) membranes. Proteins were detected using appropriate
secondary horseradish peroxidase-conjugated antibodies and visualized using a
chemiluminescence reagent (GE Healthcare, Little Chalfont, UK) or IRDye 800CW and
IRDye 680RD labelled secondary antibodies (LI-COR Biosciences). Quantification was
performed on scanned unsaturated bands using the GS800 Imaging densitometer and
Quantity One software (Bio-Rad Laboratories, Hemel Hempstead, UK) or on fluorescent
images using the Odyssey® CLx and Image Studio software (LI-COR Biosciences).
Microtubule depolymerization assay
AML cells were treated for 6 hours with mebendazole, colcemid (ThermoFisher Scientific) or
paclitaxel (Cayman Chemical Company). 1 x 106 cells were washed twice in PBS and
resuspended in 100 l depolymerization buffer (20mM Tris-HCl pH6.8, 0.14 M NaCl, 0.5%
NP-40, 1 mM MgCl2, 2 mM EGTA, 10 M paclitaxel, protease inhibitors)17 and vortexed on
maximum setting. Lysis of cells with this microtubule-stabilizing buffer preserves the
proportions of polymerized and soluble microtubules present in vivo in cells, following the
7period of drug treatment. Cells were then centrifuged at 12,000 x g for 10 min at 40C. The
supernatant was decanted and 100 l 2x reducing sample buffer added (S, soluble tubulin).
The pellet was resuspended in 100 l 1 mM CaCl2 (with protease inhibitors), incubated at
room temperature for 15 minutes, with brief vortexing and 100 l 2x reducing sample buffer
added (P, lysate pellet). Percent polymerized tubulin was calculated from the formula P/(P +
S)100 from quantified western blot bands.
Quantitative RT-PCR analysis
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen, Manchester, UK)
according to the manufacturer’s instructions. RNA was converted into cDNA using a cDNA
synthesis kit (Invitrogen, Life Technologies) according to the manufacturer’s instructions.
Samples were treated with DNase I (Invitrogen, Life Technologies) prior to reverse
transcription using the Moloney murine leukemia virus reverse transcriptase (Invitrogen, Life
Technologies).
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1Supplementary Figure Legends
Supplementary Figure 1. Mebendazole inhibits expression of c-MYB targets in AML cells.
QPCR analysis of selected c-MYB target gene expression in THP1 cells after 6 hours
treatment with DMSO or 10 M mebendazole, normalized to DMSO controls. Bars and error
bars are means and SD of three independent experiments. **P < 0.01; ***P < 0.001; ****P <
0.0001; n.s. not significant (relative to DMSO controls), one sample t test.
Supplementary Figure 2. Mebendazole inhibits growth and induces apoptosis in AML cells.
(a) The chart shows the fold change in viable cell number of AML cell lines treated with
DMSO or 10 M mebendazole, over 72 hours. Symbols and error bars are means and SD of
three independent experiments, each in triplicate. (b) Examples of Annexin V/PI staining of
THP1 cells exposed to DMSO or 10M mebendazole for 48 hours. (c) Apoptotic analysis of
AML cell lines exposed to DMSO or 10 M mebendazole, over 72 hours. Symbols,
representing the percentage of Annexin V-/PI- cells, and error bars are means and SD of three
independent experiments.
Supplementary Figure 3. Mebendazole inhibits colony formation by AML cells. Colony
formation, normalized to DMSO controls, of AML cell lines in the presence of indicated
mebendazole concentrations. Bars and error bars are means and SD of three independent
experiments, each in quadruplicate.
Supplementary Figure 4. c-MYB silencing inhibits colony formation by AML cells. (a)
Western blot analysis of c-MYB protein expression in AML cells transduced with control
scramble (SCR) shRNA or shRNA targeting c-MYB (MYB). (b) Example of colony
formation in methylcellulose cultures of shSCR or shMYB transduced THP1 cells. (c)
Colony formation, normalized to DMSO controls, of shSCR or shMYB transduced AML cell
lines. Bars and error bars are means and SD of quadruplicate cultures.
2Supplementary Figure 5. Proteasomal inhibition blocks mebendazole induced c-MYB
degradation. Quantification of c-MYB protein expression in indicated AML cells lines
following 6 hours treatment with DMSO, 10 M MBZ or 10 M MBZ/10 M MG132. Bars
and error bars are means and SD of four (THP1) and three (OCI-AML3, SHI-1) independent
experiments. Data are normalized to DMSO controls. ***P < 0.001; n.s. not significant
(relative to DMSO controls), one sample t test.
Supplementary Figure 6. Mebendazole induces c-MYB degradation at lower concentrations
than those required for tubulin depolymerization. (a) Example of western blot analysis of
tubulin depolymerization assay. Polymerized tubulin, present in the lysate pellet (P), and
soluble tubulin (S) bands are shown for THP1 cells treated for 6 hours with indicated
concentrations of mebendazole (top) or colcemid and 5 M paclitaxel (Pax) (bottom). (b)
Percent polymerized tubulin in OCI-AML3 cells following 6 hours treatment with indicated
concentrations of mebendazole (top left) or colcemid (top right), and western blot analysis of
corresponding c-MYB protein expression (bottom). Tubulin stabilization by 5 M paclitaxel
(Pax) is also shown. Bars and error bars are means and SD, respectively, of four independent
experiments. *P < 0.05; ***P < 0.001, n.s. not significant, unpaired Student’s t-test.
Supplementary Figure 7. Mebendazole induced c-MYB loss is not due to cell cycle
inhibition. (a) Quantification of c-MYB protein expression in THP1 cells following 4 hours
treatment with DMSO or indicated concentrations of mebendazole. Bars and error bars are
means and SD of four independent experiments. Data are normalized to DMSO controls. (b)
Apoptotic analysis of THP1 cells following 4 hours exposure to DMSO or 10 M
mebendazole. Bars, representing the percentage of Annexin V-/PI- cells, and error bars are
means and SD of three independent experiments. (c) Examples of flow cell cycle cytometry
plots of THP1 cells treated for 4 hours with DMSO or the indicated concentrations of
3mebendazole. Numbers inside plots are percentages of cells in Go/G1 (bottom left), S (top)
and G2/M (bottom right) phases of the cell cycle. (d and e) Bars and error bars are means and
SD of percentages of THP1 cells in the Go/G1, S and G2/M phases of the cell cycle
following 4 (d) and 24 (e) hours of treatment with DMSO or the indicated concentrations of
mebendazole, from four (d) and three (e) independent experiments. ***P < 0.001; n.s. not
significant, unpaired Student’s t-test.
Supplementary Figure 8. Nematic protein organisation technique (NPOT) analysis of
mebendazole in AML cell lysates. (a) Pictures of three independent hetero-assemblies
(circled in red) induced by mebendazole in primary AML sample AML4298 and THP1 cell
lysates. (b) Venn diagrams for the number of proteins identified in AML4298 and THP1
lysates, and in both lysates. (c) DAVID analysis and the annotation sources GOTERM_BP2
(Biological process) were used to identify the functional categories identified in AML4298
lysates. Shown in bold are the proteins comprising the ‘protein folding’ category also
identified in THP1 lysates.
Supplementary Figure 9. The HSP70/HSC70 chaperone complex binds c-MYB and is
required for maintenance of c-MYB protein expression. (a) Western blot analysis of mouse
IgG and anti-c-MYB immunoprecipitates from THP1 cells, stained with anti-HSP70/HSC70
(top) and anti-c-MYB (bottom). Representative data from one of three independent
experiments. (b) Quantification of HSP70 (left) and c-MYB (right) protein expression in
THP1 cells 7 days after transduction with control scramble (shSCR) shRNA or two
independent shRNA targeting HSPA1A (sh1 and sh2). Bars and error bars are means and SD
of three independent experiments. (c) Representative data and quantification of c-MYB
protein expression in THP-1 cells after 6 hours treatment with DMSO or the indicated
concentrations of the HSP70 inhibitors, KNK437 and VER-155008. Bars and error bars are
means and SD of three independent experiments. (d) Representative data and quantification
4of HSP70/HSC70 protein expression in total (total), cytoplasmic (cyto) and nuclear (nuc)
extracts from THP-1 cells treated with DMSO or 10 M mebendazole for 6 hours. The
extracts were validated using antibodies against Tubulin (cytoplasmic) and SP1 (nuclear),
and nuclear expression of c-MYB is also shown. Bars and error bars represent relative
HSP70/HSC70 expression in total (using Tubulin for loading), cytoplasmic (using Tubulin
for loading) and nuclear extracts (using SP1 for loading), and are means and SD of three
independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant (relative
to DMSO controls), one sample t test.
Supplementary Figure 10. Mebendazole pre-treatment inhibits colony formation by primary
AML cells but not CD34+ CB cells. (a) Example of colony formation by a primary AML
patient sample (AML1547) and a normal CD34+ cord blood sample (CB1), after pre-
treatment with DMSO or 10 M mebendazole. Cells were treated with vehicle or drug for 20
hours, washed and placed into methylcellulose culture. Colonies were grown for 14 days and
visualized by staining with 1 mg/ml p-iodonitrotetrazolium. (b) CFU-G, CFU-GM, BFU-E,
CFU-M, CFU-GEMM and total colony numbers of two independent normal CD34+ cord
blood samples (CB1, CB2) after pre-treatment with DMSO or 10 M mebendazole. Cells
were treated with vehicle or drug for 20 hours, washed and placed into methylcellulose
culture, and colony formation scored 14 days later.
Supplementary Figure 11. Mebendazole induced c-MYB loss in CB cells is less acute than
in AML cells. (a) Representative data and (b) quantification of c-MYB protein expression in
CB cells following treatment with DMSO or 10 M mebendazole for 6 hours. Prior to drug
treatment, CD34+ CB cells were expanded for 7 days. Bars and error bars are means and SD
of data from three independent CB samples. *P < 0.05 (relative to DMSO controls), one
sample t test.
5Supplementary Figure 12. In vivo drug treatment selects for increased c-MYB expression
and reduced sensitivity to mebendazole. (a) Quantification of c-MYB protein expression in
THP1 cells ex vivo (T-RES1), isolated from NSG mice following treatment with
mebendazole in vivo, compared to control THP1 cells. (b) Increased c-MYB expression is
still exhibited after two weeks in vitro culture in the absence of mebendazole. c-MYB protein
expression in THP1 cells isolated from mebendazole-treated NSG mice (T-RES1 and T-
RES2) following 2 weeks in vitro culture (in vitro). (c) c-MYB protein expression in T-RES1
cells, after 6 hours ex vivo exposure to the indicated concentrations of mebendazole,
compared to control THP1 cells. (d) Viability, normalized to DMSO controls, of control
THP1 and T-RES1 cells treated for 72 hours with indicated mebendazole concentrations.
Bars and error bars are means and SD of triplicate cultures.
Supplementary Table 1. Patient characteristics.
Patient id Sex Age (yrs) FAB Karyotype
1497 M 1.6 4 46, XY, t(9;11;9)(p22;p23;q34)
1547 F 8.8 5 46, XX, t(9;11)(p22;q23)(low% 47, idem, +8)
4298 M 11.2 5 46, XY, t(9;11)
Supplementary Table 2. Gene expression data for SPIEDw analysis.
Gene Fold change upon loss of MLL-ENL/MLL-AF9
ANTXR1 -14.040
SIX4 -9.696
P2RY2 -7.474
FRAT2 -6.627
IRAK1BP1 -5.853
IPO11 -5.278
LRIG1 -4.860
SIX1 -3.968
TASP1 -3.809
CABLES1 -3.734
MYC -3.724
MMACHC -3.586
PDCD4 -3.571
NT5DC2 -3.562
PDXK -3.490
ST7 -3.435
MID1 -3.373
SPRED1 -3.043
PFKL -3.026
HSPA2 -2.994
MRPS27 -2.957
PRMT6 -2.933
SLC39A8 -2.867
MRPS6 -2.862
MSI2 -2.786
GATA2 -2.744
UCK2 -2.714
STEAP3 -2.714
PRPF19 -2.664
CRTAP -2.642
EXOSC6 -2.631
GPR180 -2.629
LIPT1 -2.617
PAPSS2 -2.613
AHCY -2.607
EBNA1BP2 -2.563
TMEM97 -2.558
ABI2 -2.554
BAMBI -2.548
PCDH7 -2.547
TRAP1 -2.518
MINPP1 -2.490
PRPS1 -2.452
SPRED2 -2.409
POLR1E -2.275
SPRY2 -2.226
OLA1 -2.198
LIMK1 -2.182
COMMD9 -2.172
NUP35 -2.151
ACSL3 -2.149
KLHL5 -2.147
LPAR1 -2.132
DTYMK -2.103
EPRS -2.099
IDH2 -2.095
TMEM107 -2.080
TRIM45 -2.057
SASH1 -2.045
CXorf21 -2.029
BCLAF1 -2.005
NIT2 -1.992
SNRPF -1.988
IL13RA1 1.992
ECM1 2.004
AGTRAP 2.004
RUNX1 2.020
CENPJ 2.024
PSAP 2.037
PTPRC 2.041
DACH1 2.053
FMNL1 2.053
SULF2 2.058
SLA 2.070
SSH1 2.070
PTK2B 2.070
ABCG1 2.088
PLEK 2.092
INTS12 2.096
TDRD7 2.119
PLEKHO2 2.123
CDC42EP3 2.132
RBMS1 2.132
IQSEC1 2.132
FHOD1 2.141
LST1 2.146
H2AFX 2.151
NUMB 2.160
ACVR1B 2.165
ABCA13 2.165
IQGAP1 2.174
TOB1 2.174
WDR26 2.174
PLEKHA2 2.179
DMXL2 2.217
AKAP13 2.222
MAPK3 2.227
PRKCD 2.252
IFT122 2.257
PIK3CB 2.262
HBP1 2.304
SSH2 2.309
PTPRE 2.326
LPP 2.342
SH3KBP1 2.347
PYGL 2.347
MBP 2.381
WIPI1 2.381
HEXB 2.410
RTKN2 2.427
TNFAIP3 2.451
PHF21A 2.457
KLF13 2.457
GLRX 2.481
FLNA 2.488
NCF4 2.494
PSTPIP2 2.513
FLOT1 2.525
SMARCA2 2.538
NEU1 2.558
SNX10 2.558
RAC2 2.591
SIRPA 2.660
VCAN 2.667
SEMA4D 2.695
ITGAL 2.710
JAZF1 2.747
KLF6 2.762
IQGAP2 2.778
BMX 2.786
MYO1F 2.874
SORL1 2.882
LTA4H 2.890
PELI2 2.907
ACSL1 2.933
MYH9 2.933
SPSB1 2.976
SNAI3 3.012
CD9 3.012
RHBDF2 3.030
CCND3 3.040
THBS1 3.077
DOCK5 3.125
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PLAUR 3.268
ZFP36 3.390
ZYX 3.390
ZFP36L1 3.509
GLIPR2 3.636
DHRS3 3.650
NOTCH1 3.676
ST3GAL2 3.690
NFKBIZ 3.831
PLAU 3.906
LTB4R 3.922
NCF1 4.000
FGR 4.219
LYST 4.237
DAPK2 4.274
PHLDA1 4.367
BCL6 4.425
SQRDL 4.785
GPAT3 5.181
GCNT2 5.435
HLX 6.024
SERPINB2 6.452
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CAMP 9.434
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C5AR1 13.889
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